Pfizer Q4 2025 Earnings Analysis

**BETA FINCH PODCAST SCRIPT**---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from the latest quarterly reports. I'm Alex.**JORDAN**: And I'm Jordan. Before we dive in, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX**: Thanks Jordan. Today we're breaking down Pfizer's Q4 2025 earnings, and wow - this was a packed call. We've got solid financial performance, major obesity drug developments, and some really interesting strategic moves. Let's start with the numbers, Jordan.**JORDAN**: The headline numbers tell a story of resilience, Alex. Pfizer posted $62.6 billion in full-year revenue versus $63.6 billion last year - that's a 2% operational decline. But here's the key detail: when you strip out their COVID products, they actually grew operational revenue by 6%. **ALEX**: That's huge because it shows the underlying business is healthy. What about profitability?**JORDAN**: Even better news there. Adjusted earnings per share came in at $3.22 versus $3.11 last year, beating expectations. They expanded gross margins to 76%, and their recently launched and acquired products - which is really their growth engine - delivered over $10 billion in revenue with 14% operational growth.**ALEX**: Now, the elephant in the room with Pfizer has always been their COVID business decline. How bad was that impact in Q4?**JORDAN**: Pretty significant. COVID products dropped about 40% operationally year-over-year in Q4. But Alex, this is actually old news at this point. What's more interesting is how well they're managing through it. Their non-COVID business grew 9% in the quarter, driven by products like Abrysvo, Eliquis, Prevnar, and the Vyndaqel family.**ALEX**: Speaking of managing through challenges, they reaffirmed their 2026 guidance today. Walk us through what they're expecting.**JORDAN**: They're guiding for $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted EPS for 2026. What's notable is they're expecting COVID revenues to drop to about $5 billion, and they're anticipating $1.5 billion in revenue compression from generic competition. But even with those headwinds, they expect their core business excluding COVID and loss-of-exclusivity products to grow about 4% operationally.**ALEX**: Now let's talk about the real headline from today's call - their obesity drug data. This feels like a potential game-changer, Jordan.**JORDAN**: Absolutely, Alex. They announced results from their VESPER-3 study for PF-3944, which is their investigational obesity treatment. And the key differentiator here is that it's designed for monthly dosing instead of weekly like current GLP-1 drugs.**ALEX**: Monthly dosing - that's a big deal for patient convenience. What kind of weight loss are we talking about?**JORDAN**: The data showed 10-12% placebo-adjusted weight loss at 28 weeks for their planned phase 3 doses. But here's what's really interesting - their modeling suggests the higher dose they're planning could deliver nearly 16% weight loss. And importantly, they didn't see a weight loss plateau at 28 weeks, suggesting patients could lose even more weight over time.**ALEX**: How does that stack up against what's already on the market?**JORDAN**: It's competitive with existing weekly GLP-1s like Ozempic and Wegovy, but the monthly dosing is the real differentiator. During the Q&A, their commercial team emphasized that reducing from four injections per month to just one could be a major advantage for patient compliance and switching existing patients to their therapy.**ALEX**: What about side effects? That's always a concern with these obesity drugs.**JORDAN**: The safety profThis episode includes AI-generated content.